Fjarde AP Fonden Fourth Swedish National Pension Fund Increases Position in Cencora, Inc. $COR

Fjarde AP Fonden Fourth Swedish National Pension Fund grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 57.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 186,732 shares of the company’s stock after acquiring an additional 68,055 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Cencora were worth $58,660,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Kemnay Advisory Services Inc. bought a new position in Cencora during the 4th quarter valued at approximately $25,000. Oakworth Capital Inc. bought a new stake in Cencora in the fourth quarter worth $26,000. Elyxium Wealth LLC bought a new stake in Cencora in the fourth quarter worth $27,000. Archer Investment Corp grew its stake in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares during the last quarter. Finally, Motiv8 Investments LLC purchased a new stake in shares of Cencora in the fourth quarter worth $29,000. 97.52% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Lauren M. Tyler purchased 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the purchase, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. The trade was a 14.44% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.38% of the stock is currently owned by insiders.

Cencora Stock Up 2.8%

COR stock opened at $296.43 on Friday. The stock has a market capitalization of $57.67 billion, a P/E ratio of 22.73, a P/E/G ratio of 1.60 and a beta of 0.58. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The business has a fifty day moving average price of $278.14 and a 200-day moving average price of $320.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same period last year, the business earned $4.42 earnings per share. The company’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora announced that its Board of Directors has initiated a stock buyback program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on COR. William Blair initiated coverage on Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating for the company. Robert W. Baird cut their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Barclays reduced their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research note on Wednesday, June 10th. Wells Fargo & Company decreased their target price on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Finally, UBS Group upped their target price on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.